Screening for Down's syndrome. Antenatal screening has human costs.
作者信息
Venn-Treloar Josephine
出版信息
BMJ. 2002 Jan 12;324(7329):110.
Abstract
摘要
相似文献
1
Screening for Down's syndrome. Antenatal screening has human costs.
BMJ. 2002 Jan 12;324(7329):110.
2
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):768; author reply 771. doi: 10.1136/bmj.305.6856.768-a.
3
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):768; author reply 771. doi: 10.1136/bmj.305.6856.768-b.
4
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):770; author reply 771. doi: 10.1136/bmj.305.6856.770-a.
5
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):768; author reply 771. doi: 10.1136/bmj.305.6856.768.
6
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):769; author reply 771. doi: 10.1136/bmj.305.6856.769.
7
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):770; author reply 771. doi: 10.1136/bmj.305.6856.770.
8
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):771. doi: 10.1136/bmj.305.6856.771.
9
Antenatal screening for Down's syndrome. The west of Scotland's screening programme.
BMJ. 1993 Sep 11;307(6905):680. doi: 10.1136/bmj.307.6905.680.
10
Antenatal screening for Down's syndrome.
BMJ. 1992 Sep 26;305(6856):769-70; author reply 771. doi: 10.1136/bmj.305.6856.769-c.
本文引用的文献
1
Screening for Down's syndrome: effects, safety, and cost effectiveness of first and second trimester strategies.
BMJ. 2001 Aug 25;323(7310):423-5. doi: 10.1136/bmj.323.7310.423.
2
Ultrasonographic femur-tibial length ratio: a marker of Down syndrome from the late second trimester.
Am J Perinatol. 2001 Jun;18(4):217-24. doi: 10.1055/s-2001-15500.
3
Down's syndrome screening: a controversial test, with more controversy to come!
J Clin Pathol. 2000 Dec;53(12):893-8. doi: 10.1136/jcp.53.12.893.
4
Limitations of using first-trimester nuchal translucency measurement in routine screening for major congenital heart defects.
Ultrasound Obstet Gynecol. 2001 Feb;17(2):106-10. doi: 10.1046/j.1469-0705.2001.00342.x.
5
Nuchal translucency measurement and pregnancy outcome in karyotypically normal fetuses.
Ultrasound Obstet Gynecol. 2001 Feb;17(2):102-5. doi: 10.1046/j.1469-0705.2001.00341.x.
6
Six year survey of screening for Down's syndrome by maternal age and mid-trimester ultrasound scans.
BMJ. 2000 Mar 4;320(7235):606-10. doi: 10.1136/bmj.320.7235.606.
7
Integrated screening for Down's syndrome.
N Engl J Med. 1999 Dec 16;341(25):1935; author reply 1936.
8
Current and potential impact of fetal diagnosis on prevalence and spectrum of serious congenital heart disease at term in the UK. British Paediatric Cardiac Association.
Lancet. 1999 Oct 9;354(9186):1242-7 ik. doi: 10.1016/s0140-6736(99)01167-8.
9
Using fetal nuchal translucency to screen for major congenital cardiac defects at 10-14 weeks of gestation: population based cohort study.
BMJ. 1999 Jan 9;318(7176):81-5. doi: 10.1136/bmj.318.7176.81.
10
Antenatal screening for Down's syndrome.
Lancet. 1998 Oct 3;352(9134):1145. doi: 10.1016/s0140-6736(05)79785-3.
Zotero 插件